JavierAPinilla-IbarzMD

Assistant Professor, Oncologic Sciences, USF-Morsani

Overview of Dr. Pinilla-Ibarz

Dr. Javier Pinilla-Ibarz is an oncologist in Tampa, FL and is affiliated with H. Lee Moffitt Cancer Center and Research Institute. He received his medical degree from Universidad de Zaragoza Faculty of Medicine and has been in practice 29 years. Dr. Pinilla-Ibarz accepts several types of health insurance, listed below. He is one of 170 doctors at H. Lee Moffitt Cancer Center and Research Institute who specialize in Oncology. He has more than 100 publications and over 500 citings.

Office
12902 USF Magnolia Dr
MRC 3 East RM 3056H
Tampa, FL 33612
Book by Phone+1(763) 710-2045

Fax+1 813-745-6817

Education & Training

New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 2004 - 2006
Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2001 - 2004
Universidad de Zaragoza Faculty of MedicineClass of 1988

Certifications & Licensure

FL State Medical License 2006 - 2025
American Board of Internal Medicine Hematology

Awards, Honors, & Recognition

Regional Top Doctor Castle Connolly, 2014

Clinical Trials

Study Safety and Preliminary Efficacy of DCC-2036 in Patients With Leukemias (Ph+ CML With T315I Mutation) Start of enrollment: 2009 Mar 01
Completed
Phase 1
Ofatumumab, High Dose Methylprednisolone, Ofatumumab and Lenalidomide Consolidative Therapy for Untreated CLL/SLL Start of enrollment: 2012 Mar 30
Active, not recruiting
Phase 2
Ruxolitinib in Combination With Nilotinib in Chronic Myeloid Leukemia (CML) Patients Start of enrollment: 2013 Feb 21
Completed
Phase 1
A Study That Switched Patients From Imatinib to Nilotinib and Then Was Followed by Treatment Cessation Start of enrollment: 2013 Aug 12
Completed
Phase 2
Treatment Free Remission After Combination Therapy With Ruxolitinib Plus Tyrosine Kinase Inhibitors Start of enrollment: 2019 Nov 19
Recruiting
Phase 2
Roles: Contact, Principal Investigator
Join now to see all

Publications & Presentations

PubMed

222 citations
Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial.
John C. Byrd, Peter Hillmen, Paolo Ghia, Arnon P. Kater, Asher Chanan-Khan
Journal of Clinical Oncology. 2021-07-26
56 citations
Selective HDAC6 inhibitors improve anti-PD-1 immune checkpoint blockade therapy by decreasing the anti-inflammatory phenotype of macrophages and down-regulation of imm...
Tessa Knox, Eva Sahakian, Debarati Banik, Melissa Hadley, Erica Palmer
Scientific Reports. 2019-04-16
79 citations
Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK Inhibition as an Effective Strategy.
Anthony R. Mato, Lindsey E. Roeker, Ryan Jacobs, Brian T. Hill, Nicole Lamanna
Clinical Cancer Research. 2020-07-15

Journal Articles

A Phase I Clinical Trial of Ruxolitinib in Combination with Nilotinib in Chronic Myeloid Leukemia Patients with Molecular Evidence of Disease
Kendra Sweet, Fadi Kayali, Javier Pinilla-Ibarz, Leukemia Research
A Phase I Clinical Trial of Ruxolitinib in Combination with Nilotinib in Chronic Myeloid Leukemia Patients with Molecular Evidence of Disease
Kendra Sweet, Fadi Kayali, Javier Pinilla-Ibarz, Leukemia Research

Abstracts/Posters

Moffitt Cancer Center 2-Year Single-Institution Experience with Next-Generation Sequencing Minimal Residual Disease Detection: Clinical Utility, Application, and Corre...
Javier Pinilla Ibarz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Patient-Reported Outcome Results from the U.S. Life after Stopping TKIs (LAST) Study in Patients with Chronic Myeloid Leukemia
Javier Pinilla Ibarz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Impact of Rituximab in the Clinical Outcomes of Hairy Cell Leukemia: A Retrospective Single-Institution Analysis
Javier Pinilla Ibarz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Selective Targeting of Histone Deacetylase 11 Disables Metabolism of Myeloproliferative Neoplasms
Javier Pinilla Ibarz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Join now to see all

Lectures

Loss of HDAC11 Promotes Myeloid-Derived Suppressor Cells Inhibition of T Cell Function in a Murine Lymphoma Microenvironment
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Authored Content

A Phase I Clinical Trial of Ruxolitinib in Combination with Nilotinib in Chronic Myeloid Leukemia Patients with Molecular Evidence of DiseaseOctober 2018

Press Mentions

S1712 Supports Adding Ruxolitinib to TKIs for CMLSeptember 20th, 2024
Precigen Announces Clearance of IND to Initiate Phase 1/1b Study for PRGN-3007 UltraCAR-T® in Advanced ROR1+ Hematological and Solid TumorsOctober 26th, 2021
Experts Emphasize Importance of Preventing Progression in CMLJanuary 29th, 2016
Join now to see all

Insurance Accepted

Aetna Choice POS II
Aetna HMO
AvMed Health Open Access
BCBS Blue Card PPO
BCBS Florida BlueCare HMO
BCBS Florida NetworkBlue
BCBS Florida Preferred Patient Care PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPO
Coventry Florida - Employer Group PPO
First Health PPO
Great West PPO
Health Net Oregon PPO
Humana ChoiceCare Network PPO
Multiplan PHCS PPO
Multiplan PPO
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO
Please verify your coverage with the provider's office directly when scheduling an appointment